Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies. It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK. Cerdulatinib is a reversible ATP-competitive dual JAK and Syk inhibitor. The FDA granted orphan drug status to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL).